Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) EBT Margin (2016 - 2026)

Cytosorbents filings provide 15 years of EBT Margin readings, the most recent being 70.46% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 9739.0% to 70.46% in Q4 2025 year-over-year; TTM through Dec 2025 was 42.59%, a 1300.0% decrease, with the full-year FY2025 number at 25.92%, up 410.0% from a year prior.
  • EBT Margin hit 70.46% in Q4 2025 for Cytosorbents, down from 37.65% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 167.57% in Q4 2023 to a low of 150.42% in Q3 2022.
  • Median EBT Margin over the past 5 years was 56.09% (2023), compared with a mean of 50.34%.
  • Biggest five-year swings in EBT Margin: soared 18736bps in 2023 and later crashed -14063bps in 2024.
  • Cytosorbents' EBT Margin stood at 93.14% in 2021, then skyrocketed by 79bps to 19.79% in 2022, then skyrocketed by 947bps to 167.57% in 2023, then tumbled by -84bps to 26.94% in 2024, then crashed by -362bps to 70.46% in 2025.
  • The last three reported values for EBT Margin were 70.46% (Q4 2025), 37.65% (Q3 2025), and 44.0% (Q2 2025) per Business Quant data.